EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation

Lucas W Rowe iD, S Patricia Becerra iD, Robert E MacLaren, Robert L Avery, Charles C Wykoff iD, Allen C Ho, Carl D Regillo, Dean Eliott, Andrew Osborne, Katie M Binley, Thomas A Ciulla iD

Genes · 30.03.2026 · 17 (4) · 392

DOI: 10.3390/genes17040392 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 30.03.2026. Verfasst von Lucas W Rowe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Retinal Diseases, Neuroprotection, Immunomodulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Inherited retinal diseases (IRDs) represent a genetically heterogeneous group of disorders caused by mutations in over 280 genes with more than 3100 identified variants. While gene-specific replacement therapies have achieved landmark success with voretigene neparvovec (Luxturna) for biallelic RPE65-associated retinal dystrophy, developing individual therapies for each genetic subtype remains impractical. This review examines gene-agnostic therapeutic approaches utilizing neuroprotection and immunomodulation that target common pathophysiological mechanisms shared across multiple IRD genotypes.

Methods

We reviewed the literature on neuroprotective and immunomodulatory gene therapy strategies for IRDs, focusing on neurotrophic factors and complement system modulation.

Results

Neuroprotective approaches delivering neurotrophic factors—including pigment epithelium-derived factor (PEDF), ciliary neurotrophic factor (CNTF), rod-derived cone viability factor (RdCVF), brain-derived neurotrophic factor (BDNF), fibroblast growth factors (FGFs), glial cell line-derived neurotrophic factor (GDNF), and proinsulin—have demonstrated photoreceptor preservation across multiple preclinical IRD models regardless of the underlying genetic mutation. The recent FDA approval of CNTF cell-based gene therapy (Encelto) for macular telangiectasia type 2 validates this therapeutic paradigm. Complement system inhibition represents another gene-agnostic strategy, with intravitreal complement inhibitors approved for geographic atrophy secondary to age-related macular degeneration and gene therapy approaches targeting C3, C5, or delivering soluble complement regulators under investigation for IRDs. Combination strategies simultaneously addressing multiple pathogenic pathways may offer synergistic benefits.

Conclusions

Gene-agnostic approaches targeting neuroprotection and immunomodulation offer a therapeutic paradigm capable of benefiting patients across the spectrum of IRD genotypes, potentially transforming treatment for conditions where mutation-specific therapies remain unavailable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyRetinal DiseasesNeuroprotectionImmunomodulationHumansAnimalsGene Therapy AgentsCiliary Neurotrophic Factor

Stichwörter der Autor:innen

gene agnosticgene therapyimmunomodulationinherited retinal diseaseneuroprotection

Substanzen

Ciliary Neurotrophic Factor

Autor:innen und Institutionen

  • Department of Ophthalmology, Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
  • Laboratory of Retinal Cell and Molecular Biology, Section of Protein Structure and Function, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK.
  • Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
  • California Retina Consultants, Santa Barbara, CA 93103, USA.
  • Retina Consultants of Texas, Bellaire, TX 77401, USA.

ORCID-Profile: Lucas W Rowe, S Patricia Becerra, Charles C Wykoff, Thomas A Ciulla

Zitieren

APA

Rowe, L. W., Becerra, S. P., MacLaren, R. E., Avery, R. L., Wykoff, C. C., Ho, A. C., Regillo, C. D., Eliott, D., Osborne, A., Binley, K. M., & Ciulla, T. A. (2026). Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation. Genes, 17(4), 392. https://doi.org/10.3390/genes17040392

Vancouver

Rowe LW, Becerra SP, MacLaren RE, Avery RL, Wykoff CC, Ho AC, et al. Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation. Genes. 2026;17(4):392. doi:10.3390/genes17040392

BibTeX
@article{Rowe2026,
  author = {Rowe, Lucas W and Becerra, S Patricia and MacLaren, Robert E and Avery, Robert L and Wykoff, Charles C and Ho, Allen C and Regillo, Carl D and Eliott, Dean and Osborne, Andrew and Binley, Katie M and Ciulla, Thomas A},
  title = {Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation},
  journal = {Genes},
  year = {2026},
  volume = {17},
  number = {4},
  pages = {392},
  doi = {10.3390/genes17040392}
}
Kostenlos starten →